Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue (2021)
Amylyx Pharmaceuticals (AMLX) posted quarterly Non-Current Deffered Revenue of $35000.0 for Q4 2021.
Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue (2021) Analysis & Trends
Amylyx Pharmaceuticals' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $35000.0 for Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue changed N/A year-over-year to $35000.0; the TTM figure through Dec 2021 stood at $35000.0 (changed N/A YoY), while the FY2021 annual figure was $35000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2021 stood at $35000.0.
- The five-year high for Non-Current Deffered Revenue was $35000.0 in Q4 2021, with the low at $35000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 35,000.00 |